Saved in:
Bibliographic Details
Main Authors: Marco Oderda, Giulia Orlando, Giorgio Calleris, Giulia Capella, Luisa Delsedime, Eleonora Duregon, Paola Francia di Celle, Donatella Pacchioni, Ian Marc Bonapace, Zaibunnisa Zaibunnisa, Daniele D'Agate, Gabriele Montefusco, Claudia Filippini, Mauro Papotti, Paolo Gontero
Format: Artículo Open Access
Published: Wiley 2025
Subjects:
Online Access:https://onlinelibrary.wiley.com/doi/10.1002/pros.24921
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867018914064498688
author Marco Oderda
Giulia Orlando
Giorgio Calleris
Giulia Capella
Luisa Delsedime
Eleonora Duregon
Paola Francia di Celle
Donatella Pacchioni
Ian Marc Bonapace
Zaibunnisa Zaibunnisa
Daniele D'Agate
Gabriele Montefusco
Claudia Filippini
Mauro Papotti
Paolo Gontero
author_facet Marco Oderda
Giulia Orlando
Giorgio Calleris
Giulia Capella
Luisa Delsedime
Eleonora Duregon
Paola Francia di Celle
Donatella Pacchioni
Ian Marc Bonapace
Zaibunnisa Zaibunnisa
Daniele D'Agate
Gabriele Montefusco
Claudia Filippini
Mauro Papotti
Paolo Gontero
Marco Oderda
Giulia Orlando
Giorgio Calleris
Giulia Capella
Luisa Delsedime
Eleonora Duregon
Paola Francia di Celle
Donatella Pacchioni
Ian Marc Bonapace
Zaibunnisa Zaibunnisa
Daniele D'Agate
Gabriele Montefusco
Claudia Filippini
Mauro Papotti
Paolo Gontero
collection Wiley Open Access
contents Role of Cell‐Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2‐ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance Marco Oderda Giulia Orlando Giorgio Calleris Giulia Capella Luisa Delsedime Eleonora Duregon Paola Francia di Celle Donatella Pacchioni Ian Marc Bonapace Zaibunnisa Zaibunnisa Daniele D'Agate Gabriele Montefusco Claudia Filippini Mauro Papotti Paolo Gontero The Prostate ABSTRACTBackgroundAn accurate estimation of progression risk in patients with prostate cancer (PCa) amenable to active surveillance (AS) is still an unmet need. Among available biomarkers, we considered Prolaris cell‐cycle progression (CCP) test, “triple hit” phenotype (ERG overexpression, PTEN and prostein expression loss) and elevated expression levels of TMPRSS2‐ERG gene fusions.MethodsWe performed a case‐control study, enrolling patients that entered the AS programme at our tertiary referral Institution. Men subsequently undergoing radical prostatectomy for progression were considered as “cases”, while men still on AS at the end of the follow‐up period were labeled as “controls”. CCP test, triple hit and TMPRSS2‐ERG expression analyses were performed on tumoral tissue retrieved from biopsies at enrollment. Their ability to distinguish “cases” and “controls” was evaluated. According to power analysis, the study required 40 patients.ResultsPatients had comparable baseline characteristics. CCP test suggested to continue AS in 75% of controls and to undergo an active treatment in 75% of cases. CCP molecular score (HR 8.5, p = 0.02) was significantly associated with progression in multivariable logistic regression. No significant differences were found in terms of “triple hit” or TMPRSS2:ERG expression. IHC analysis was feasible only in 17 patients due to insufficient material.ConclusionsCCP test may be a useful tool to estimate the risk of progression in PCa patients and guide the decision between AS and active treatment. Triple hit phenotype or TMPRSS:ERG fusion status was not associated with progression. 10.1002/pros.24921 http://creativecommons.org/licenses/by/4.0/
doi_str_mv 10.1002/pros.24921
format Artículo Open Access
id wiley_oa_10_1002_pros_24921
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Role of Cell‐Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2‐ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance
Marco Oderda
Giulia Orlando
Giorgio Calleris
Giulia Capella
Luisa Delsedime
Eleonora Duregon
Paola Francia di Celle
Donatella Pacchioni
Ian Marc Bonapace
Zaibunnisa Zaibunnisa
Daniele D'Agate
Gabriele Montefusco
Claudia Filippini
Mauro Papotti
Paolo Gontero
The Prostate
Role of Cell‐Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2‐ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance Marco Oderda Giulia Orlando Giorgio Calleris Giulia Capella Luisa Delsedime Eleonora Duregon Paola Francia di Celle Donatella Pacchioni Ian Marc Bonapace Zaibunnisa Zaibunnisa Daniele D'Agate Gabriele Montefusco Claudia Filippini Mauro Papotti Paolo Gontero The Prostate ABSTRACTBackgroundAn accurate estimation of progression risk in patients with prostate cancer (PCa) amenable to active surveillance (AS) is still an unmet need. Among available biomarkers, we considered Prolaris cell‐cycle progression (CCP) test, “triple hit” phenotype (ERG overexpression, PTEN and prostein expression loss) and elevated expression levels of TMPRSS2‐ERG gene fusions.MethodsWe performed a case‐control study, enrolling patients that entered the AS programme at our tertiary referral Institution. Men subsequently undergoing radical prostatectomy for progression were considered as “cases”, while men still on AS at the end of the follow‐up period were labeled as “controls”. CCP test, triple hit and TMPRSS2‐ERG expression analyses were performed on tumoral tissue retrieved from biopsies at enrollment. Their ability to distinguish “cases” and “controls” was evaluated. According to power analysis, the study required 40 patients.ResultsPatients had comparable baseline characteristics. CCP test suggested to continue AS in 75% of controls and to undergo an active treatment in 75% of cases. CCP molecular score (HR 8.5, p = 0.02) was significantly associated with progression in multivariable logistic regression. No significant differences were found in terms of “triple hit” or TMPRSS2:ERG expression. IHC analysis was feasible only in 17 patients due to insufficient material.ConclusionsCCP test may be a useful tool to estimate the risk of progression in PCa patients and guide the decision between AS and active treatment. Triple hit phenotype or TMPRSS:ERG fusion status was not associated with progression. 10.1002/pros.24921 http://creativecommons.org/licenses/by/4.0/
title Role of Cell‐Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2‐ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance
topic The Prostate
url https://onlinelibrary.wiley.com/doi/10.1002/pros.24921